InsiderSignal.AI

InsiderSignal.ai

FOLD - Amicus Therapeutics, Inc.

Insider Sale by Campbell Bradley L (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Campbell Bradley L, serving as Pres, CEO at Amicus Therapeutics, Inc. (FOLD), sold 22,500 shares at $14.35 per share, for a total transaction value of $322,839.00. Following this transaction, Campbell Bradley L now holds 998,680 shares of FOLD.

This sale represents a 2.00% decrease in Campbell Bradley L's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, March 2, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 4, 2026, 2 days after the trade was made.

Amicus Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Campbell Bradley L

Campbell Bradley L

Pres, CEO

Bradley L. Campbell is the President and Chief Executive Officer (CEO) of Amicus Therapeutics, Inc. (FOLD), a biotechnology company focused on discovering, developing, and commercializing treatments for rare and orphan diseases.[[2]](https://theorg.com/org/amicus-therapeutics/org-chart/bradley-l-campbell)[[3]](https://www.zoominfo.com/bio/who-is-the-ceo-of-amicus-therapeutics-inc/22534043) He has served in this role since advancing from President and Chief Operating Officer, a position he held since joining the company in 2006.[[2]](https://theorg.com/org/amicus-therapeutics/org-chart/bradley-l-campbell) Campbell brings extensive experience in the biopharmaceutical industry, starting his career as an Analyst at Marakon (1997-1999), followed by roles at Bristol-Myers Squibb as Associate Manager in Neuroscience, Infectious Diseases, and Dermatology, and Manager of Strategy and Operations (1999-2002).[[2]](https://theorg.com/org/amicus-therapeutics/org-chart/bradley-l-campbell) He then worked at Genzyme as Senior Product Manager for Myozyme and Business Director for Cardiovascular (2002-2006).[[2]](https://theorg.com/org/amicus-therapeutics/org-chart/bradley-l-campbell) Educationally, he holds an MBA in Business Administration from Harvard Business School (2000-2002) and a BA in Public Policy Studies from Duke University (1993-1997).[[2]](https://theorg.com/org/amicus-therapeutics/org-chart/bradley-l-campbell)[[3]](https://www.zoominfo.com/bio/who-is-the-ceo-of-amicus-therapeutics-inc/22534043) He also serves as a Board Member for Amicus Therapeutics.[[3]](https://www.zoominfo.com/bio/who-is-the-ceo-of-amicus-therapeutics-inc/22534043)

View full insider profile →

Trade Price

$14.35

Quantity

22,500

Total Value

$322,839.00

Shares Owned

998,680

Trade Date

Monday, March 2, 2026

3 days ago

SEC Filing Date

Wednesday, March 4, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Amicus Therapeutics, Inc.

Company Overview

No company information available
View news mentioning FOLD

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4500754

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime